Phase II Study of FDG-PET Guided Small Volume Accelerated Chemoradiotherapy and Durvalumab Immunotherapy in Adults with Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer
Led by TheraOp · Updated on 2025-12-17
110
Participants Needed
11
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for patients with locally advanced, unresectable Stage III non-small cell lung cancer NSCLC. This randomized, controlled phase II trial compares two radiotherapy methods combined with chemotherapy to assess completion rates and other outcomes. After chemoradiotherapy, patients receiving stable or improved disease will get consolidation immunotherapy with durvalumab for up to 12 months or until disease progression or other stopping criteria.
Participants are assigned to one of two groups one receives standard FDG-PET-based radiotherapy with concurrent chemotherapy, and the other receives FDG-PET-based small volume accelerated radiotherapy with concurrent chemotherapy. Following initial treatment, those with complete response, partial response, or stable disease continue with durvalumab immunotherapy. The study includes a safety follow-up period of about three months after durvalumab therapy ends, then survival follow-up until two years after the last patient starts durvalumab.
During the study, participants undergo FDG-PET CT scans, pulmonary function tests, and laboratory tests to monitor health and treatment effects. Researchers track treatment completion rates, adverse events, disease progression, symptom changes, quality of life, and survival outcomes over several months to years. The study also assesses radiotherapy quality and requires patients to comply with scheduled visits and testing throughout the treatment and follow-up periods.
CONDITIONS
Brief Title
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
Research Team
B
Bernhard Remes, Dr.
S
Sascha Herzer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of locally advanced, unresectable Stage III non-small cell lung cancer confirmed by histology or cytology
Fit for simultaneous chemoradiotherapy and consolidation immunotherapy
PD-L1 expression of 1% or higher in tumor sample
ECOG performance status of 0 or 1
FDG-PET CT tumor assessment within 21 days before starting chemoradiotherapy
Adequate lung function: forced expiratory volume ≥1.0 L or >40% predicted and DLCO >30% predicted
Adequate bone marrow and organ function (specified blood counts and liver/kidney function)
Body weight above 30 kg
Women must be post-menopausal or have a negative pregnancy test if of childbearing potential
Agreement to use effective contraception during treatment and for defined periods after treatment
You will not qualify if you...
Mixed small cell and non-small cell lung cancer histology
Neuroendocrine tumor
Presence of distant metastases
Malignant pleural or pericardial effusion
Acute superior vena cava obstruction
Prior or current cancer treatment for NSCLC (except limited prior surgery for early NSCLC)
Live attenuated vaccine within 30 days before treatment
Major surgery within 28 days before treatment
Previous immune therapy including anti-PD-1/PD-L1 agents
Ongoing long-term immunosuppressive medication, except low-dose or local steroids
History of organ transplantation
Active or prior autoimmune or inflammatory disorders, with some exceptions
Uncontrolled illness including infection, heart failure, hypertension, arrhythmia, lung disease, serious GI conditions, or psychiatric/social issues
Oxygen dependence
Active mediastinal lymph node inflammation due to certain diseases
History of other malignancies unless treated and stable
History of leptomeningeal carcinomatosis
Active hepatitis B, hepatitis C, tuberculosis, or HIV infection
Allergy to chemotherapy or durvalumab
Contraindication to platinum-based chemotherapy
Disease suitable for surgical treatment
Concurrent enrollment in other interventional clinical studies
Pregnancy or breastfeeding
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 12 months or until progression, unacceptable toxicity, or withdrawal
Participants receive standard or experimental FDG-PET-based radiotherapy with concurrent standard chemotherapy, followed by consolidation immunotherapy with durvalumab for up to 12 months or until disease progression, unacceptable toxicity, or other reasons.
Weekly visits during chemoradiotherapy and monthly visits during immunotherapy consolidation
Follow-up
Duration - Up to approximately 33 months (143.5 weeks) after randomization
Participants are monitored for disease progression, adverse events, and overall health after treatment completion.
Periodic visits as scheduled for up to 33 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Open-Label Study Evaluating Oral REC-1245 in Participants Aged 12 and Older With Unresectable, Locally Advanced, or Metastatic Solid Tumors and Lymphomas
Phase 12 Study of IOV-4001 Infusion for Adults with Unresectable or Metastatic Melanoma and Advanced Non-small-cell Lung Cancer
Evaluation of AVZO-1418 Safety, Dosage, and Antitumor Activity Alone and with Combination Therapy in Patients with Advanced or Metastatic Solid Tumors
Study of AVZO-103 as a Single Agent and in Combination Therapy for Advanced Urothelial Cancer and Other Solid Tumors Evaluating Safety and Antitumor Activity
Postoperative Radiotherapy with Kidney-Sparing Surgery for High-Risk Locally Advanced Ureteral Cancer
Phase 2 Study of CUE-101 Alone and With Pembrolizumab as Pre-Surgery Treatment for Adults with New Locally Advanced HPV-16 Positive Head and Neck Cancer
Study of Digital Symptom Monitoring During Cabozantinib and Nivolumab Treatment for Advanced Clear-cell Kidney Cancer
Early Study of YntraDose, a New Internal Radiation Treatment Combined With Chemotherapy for Unresectable Locally Advanced Pancreatic Cancer
Phase 2 Study of PD-1 Antibody with Platinum-based Chemotherapy
for Locally Advanced Non-small Cell Lung Cancer
Evaluating Chemoimmunotherapy Followed by Surgery or Radiotherapy
Neoadjuvant Iparomlimab and Tuvonralimab Combined with Paclitaxel and Platinum Chemotherapy
for Treating Locally Advanced Cervical Cancer in Women
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) - a randomized, open-label, multicenter phase II trial protocol.